Are there guidelines for the responsible prescription of benzodiazepines?
Addiction Division, University of Calgary, Calgary, Alberta. nady.el-Guebaly@albertahealthservices.ca
Nady
N
el-Guebaly
Jitender
J
Sareen
Murray B
MB
Stein
D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy / Q000523:psychology; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D002170:Canada; D004363:Drug Utilization / Q000706:statistics & numerical data; D017408:Guidelines as Topic; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000523:psychology; D010818:Practice Patterns, Physicians'; D055553:Prescription Drugs / Q000627:therapeutic use*; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D019966:Substance-Related Disorders / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014481:United States
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D055553:Prescription Drugs; D017367:Selective Serotonin Reuptake Inhibitors